Paesmans M., Sculier J.-P. (1998) Facteurs pronostiques des cancers bronchopulmonaires. Cancers Bronchopulmonaires , Milleron B, Depierre A eds. France, Arnette; 239-247.
Paesmans M., Sculier J.P., Lecomte J. (2000) Prognostic factors in patients with small cell lung cancer: Analysis of a series of 763 patients included in four consecutive prospective trials and with a minimal 5-year follow-up duration. Cancer , for the European Lung Cancer Working Party.; 89:523-533.
Strauss G.M. (1997) Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am 11:409-434.
Paesmans M., Sculier J.P., Libert P. (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol , The European Lung Cancer Working Party.; 13:1221-1230.
Buccheri G., Ferrigno D. (1994) Prognostic factors in lung cancer: Tables and comments. Eur Respir J 7:1350-1364.
Kanters S.D., Lammers J.W., Voest E.E. (1995) Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8:1389-1397.
O'Byrne K.J., Koukourakis M.I., Giatromanolaki A. (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angio-genesis in non-small cell lung cancer. Br J Cancer 82:1427-1432.
Brambilla E., Negoescu A., Gazzeri S. (1996) Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149:1941-1952.
D'Amico T.A., Massey M., Herndon J.E., Moore M.B., Harpole D.H. Jr. (1999) A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743.
Kim Y.C., Park K.O., Kern J.A. (1998) The interactive effect of Ras, HER2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 22:181-190.
Kwiatkowski D.J., Harpole D.H. Jr., Godleski J. (1998) Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J Clin Oncol 16:2468-2477.
Ferreira C.G., Tolis C., Giaccone G. (1999) P53 and chemosensitivity. Ann Oncol 10:1011-1021.
Brambilla E., Brambilla C. (1997) P53 and lung cancer. Pathol Biol (Paris) 45:852-863.
Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
Parmar M.K.B., Torri V., Stewart L. (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med 17:2815-2834.
Yusuf S., Peto R., Lewis J., Collins R., Sleight P. (1985) Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27:335-371.
Apolinario R.M., Van der V., De Jong J.S. (1997) Prognostic value of the expression of p53, Bcl-2, and Bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15:2456-2466.
Bergqvist M., Brattstrom D., Larsson A. (1998) P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 18:1999-2002.
Brambilla E., Gazzeri S., Moro D. (1993) Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-210.
Carbone D.P., Mitsudomi T., Chiba I. (1994) P53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A Preliminary Report of LCSG 871. Chest 106.
Chen Y., Sato M., Fujimura S. (1999) Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res 19:1351-1356.
Dalquen P., Sauter G., Torhorst J. (1996) Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 178:53-58.
De Anta J.M., Jassem E., Rosell R. (1997) TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: Null mutations are associated with poor prognosis. Oncogene 15:2951-2958.
Dobashi K., Sugio K., Osaki T., Oka T., Yasumoto K. (1997) Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: Prognostic significance. J Thorac Cardiovasc Surg 114:339-346.
Dosaka-Akita H., Hu S.X., Fujino M. (1997) Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered Ras and p53 protein status on prognosis. Cancer 79:1329-1337.
Ebina M., Steinberg S.M., Mulshine J.L., Linnoila R.I. (1994) Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496-2503.
Esposito V., Baldi A., De Luca A. (1997) Prognostic value of p53 in non-small cell lung cancer: Relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 28:233-237.
Fontanini G., Vignati S., Bigini D. (1995) Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71:1003-1007.
Fontanini G., Vignati S., Bigini D. (1996) Recurrence and death in non-small cell lung carcinomas: A prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res 2:1067-1075.
Fontanini G., Boldrini L., Vignati S. (1998) Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 34:718-723.
Fu X.L., Zhu X.Z., Shi D.R. (1999) Study of prognostic predictors for non-small cell lung Cancer. Lung Cancer 23:143-152.
Fujino M., Dosaka-Akita H., Harada M. (1995) Prognostic significance of p53 and Ras P21 expression in nonsmall cell lung cancer. Cancer 76:2457-2463.
Fukuyama Y., Mitsudomi T., Sugio K., Ishida T., Akazawa K., Sugimachi K. (1997) K-Ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 75:1125-1130.
Geradts J., Fong K.M., Zimmerman P.V., Maynard R., Minna J.D. (1999) Correlation of abnormal RB, P16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5:791-800.
Giatromanolaki A., Koukourakis M., O'Byrne K. (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80-88.
Greatens T.M., Niehans G.A., Rubins J.B. (1998) Do molecular markers predict survival in non-small-cell lung cancer?. Am J Respir Crit Care Med 157:1093-1097.
Guang S.G., Ogura T., Sekine I. (1997) Association between p53 mutation and clinicopathological features of non-small cell lung cancer. Jpn J Clin Oncol 27:211-215.
Harpole D.H. Jr., Marks J.R., Richards W.G., Herndon J.E., Sugarbaker D.J. (1995) Localized adenocarcinoma of the lung: Oncogene expression of ErbB-2 and p53 in 150 patients. Clin Cancer Res 1:659-664.
Harpole D.H. Jr., Herndon J.E., Wolfe W.G. (1995) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55:51-56.
Harpole D.H. Jr., Richards W.G., Herndon J.E., Sugarbaker D.J. (1996) Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470-1476.
Hayakawa K., Mitsuhashi N., Hasegawa M. (1998) The prognostic significance of immunohistochemically detected p53 protein expression in non-small cell lung cancer treated with radiation therapy. Anticancer Res 18:3685-3688.
Horio Y., Takahashi T., Kuroishi T. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1-4.
Huang C.L., Taki T., Adachi M. (1998) Mutations of p53 and K-Ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 12:553-563.
Huang C., Taki T., Adachi M., Konishi T., Higashiyama M., Miyake M. (1998) Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16:2469-2477.
Ishida H., Irie K., Itoh T., Furukawa T., Tokunaga O. (1997) The prognostic significance of p53 and Bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 80:1034-1045.
Kandioler-Eckersberger D., Kappel S., Mittlbock M. (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 117:744-750.
Kawasaki M., Noguchi M., Morikawa A. (1996) Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Pathol Int 46:486-490.
Kawasaki M., Nakanishi Y., Kuwano K., Yatsunami J., Takayama K., Hara N. (1997) The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 3:1195-1200.
Komaki R., Milas L., Ro J.Y. (1998) Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 40:787-796.
Komiya T., Hirashima T., Takada M. (1997) Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 17:3721-3724.
Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., Monden Y.A. (1996) Dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61:20-26.
Konishi T., Lin Z., Fujino S., Kato H., Mori A. (1997) Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Hum Pathol 28:544-548.
Kwa H.B., Michalides R.J., Dijkman J.H., Mooi W.J. (1996) The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer 14:207-217.
Lai C.L., Tsai C.M., Tsai T.T. (1998) Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 4:3025-3030.
Langendijk J.A., Thunnissen F.B., Lamers R.J. (1995) The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol 36:218-224.
Laudanski J., Burzykowski T., Niklinska W., Chyczewski K., Furman M., Niklinski J. (1998) Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer 22:191-200.
Lavezzi A.M., Santambrogio L., Bellaviti N. (1999) Prognostic significance of different biomarkers in non-small cell lung cancer. Oncol Rep 6:819-825.
Lee J.S., Yoon A., Kalapurakal S.K. (1995) Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor. J Clin Oncol 13:1893-1903.
Levesque M.A., D'Costa M., Spratt E.H., Yaman M.M., Diamandis E.P. (1998) Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. Int J Cancer 79:494-501.
Lohmann D., Putz B., Reich U., Bohm J., Prauer H., Hofler H. (1993) Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 142:907-915.
Lucchi M., Fontanini G., Mussi A. (1997) Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 12:535-541.
Macchiarini P., Fontanini G., Dulmet E. (1994) Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 57:1534-1539.
MacKinnon M., Kerr K.M., King G., Kennedy M.M., Cockburn J.S., Jeffrey R.R. (1997) P53, C-ErbB-2 and Nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. Eur J Cardiothorac Surg 11:838-842.
McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter K.C. (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738.
Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85:2018-2023.
Mitsudomi T., Suzuki S., Yatabe Y. (1998) Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 90:1563-1568.
Miyake M., Adachi M., Huang C., Higashiyama M., Kodama K., Taki T. (1999) A novel molecular staging protocol for non-small cell lung cancer. Oncogene 18:2397-2404.
Moldvay J., Strausz J., Egervary M. (1998) P53 expression in stage i squamous cell lung cancer. Pathol Oncol Res 4:8-13.
Morkve O., Halvorsen O.J., Skjaerven R., Stangeland L., Gulsvik A., Laerum O.D. (1993) Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 13:571-578.
Murakami I., Fujiwara Y., Yamaoka N., Hiyama K., Ishioka S., Yamakido M. (1996) Detection of p53 gene mutations in cytopathology and biopsy specimens from patients with lung cancer. Am J Respir Crit Care Med 154:1117-1123.
Nishio M., Koshikawa T., Kuroishi T. (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14:497-502.
Nishio M., Koshikawa T., Yatabe Y. (1997) Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 3:1051-1058.
O'Neill A.J., Staunton M.J., Gaffney E.F. (1996) Apoptosis occurs independently of Bcl-2 and p53 over-expression in non-small cell lung carcinoma. Histopathology 29:45-50.
Ohsaki Y., Toyoshima E., Fujiuchi S. (1996) Bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time. Clin Cancer Res 2:915-920.
Pappot H., Francis D., Brunner N., Grondahl-Hansen J., Osterlind K. (1996) P53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: Relation to prognosis. Clin Cancer Res 2:155-160.
Pastorino U., Andreola S., Tagliabue E. (1997) Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 15:2858-2865.
Przygodzki R.M., Finkelstein S.D., Langer J.C. (1996) Analysis of p53, K-Ras-2, and C-Raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 148:1531-1541.
Quantin X., Pujol J.L., Lehmann M., Simony J., Serre I., Michel F.B. (1997) Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer. Cancer Detect Prev 21:418-425.
Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831.
Roncalli M., Doglioni C., Springall D.R. (1992) Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications. Diagn Mol Pathol 1:129-135.
Rosell R., Pifarre A., Monzo M. (1997) Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer 74:330-334.
Rosenfeld M.R., Malats N., Schramm L. (1997) Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 89:381-385.
Tagawa M., Murata M., Kimura H. (1998) Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: Association with clinicopathological features. Cancer Lett 128:93-99.
Tanaka F., Miyahara R., Ohtake Y. (1998) Antigen expression and postoperative survival in non-small cell lung cancer. Ann Thorac Surg 66:1745-1750.
Tanaka F., Yanagihara K., Ohtake Y. (1999) P53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Jpn J Cancer Res 90:432-438.
Tomizawa Y., Kohno T., Fujita T. (1999) Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18:1007-1014.
Tomizawa Y., Adachi J., Kohno T. (1999) Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma. Clin Cancer Res 5:1139-1146.
Top B., Mooi W.J., Klaver S.G. (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 64:83-91.
Tormanen U., Eerola A.K., Rainio P. (1995) Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55:5595-5602.
Vega F.J., Iniesta P., Caldes T. (1997) P53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br J Cancer 76:44-51.
Volm M., Efferth T., Mattern J. (1992) Oncoprotein (c-Myc, C-ErbB1, C-ErbB2, C-Fos) and Suppressor Gene Product (P53) Expression in Squamous Cell Carcinomas of the Lung. Clinical and Biological Correlations. Anticancer Res 12:11-20.
Xu H.J., Cagle P.T., Hu S.X., Li J., Benedict W.F. (1996) Altered retinoblastoma and 12p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis. Clin Cancer Res 2:1169-1176.
Swisher S.G., Roth J.A., Nemunaitis J. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91:763-771.
Sculier J.P., Berghmans T., Castaigne C. (1998) Maintenance chemotherapy for small cell lung cancer: A critical review of the literature. Lung Cancer 19:141-151.
Luce S., Paesmans M., Berghmans T. (1998) Revue critique des études randomisées évaluant le rôle de la radiothérapie dans le traitement du cancer bronchique à petites cellules au stade limité. Rev Mal Respir 15:633-641.
Meert A.P., Berghmans T., Branle F. (1999) Phase II and III with new drugs for non-small cell lung cancer: A systematic review of the literature with a methodology quality assessment. Anticancer Res 19:4379-4390.
Mascaux C., Paesmans M., Berghmans T. (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23-26.
Egger M., Zellweger-Zahner T., Schneider M., Junker C., Lengeler C., Antes G. (1997) Language bias in randomised controlled trials published in English and German. Lancet 350:326-329.
Hollstein M., Sidransky D., Vogelstein B., Harris C.C. (1991) P53 mutations in human cancers. Science 253:49-53.
Levine A.J., Perry M.E., Chang A. (1994) The 1993 Walter Hubert lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69:409-416.
Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355.
Tominaga O., Hamelin R., Remvikos Y., Salmon R.J., Thomas G. (1992) P53 from basic research to clinical applications. Crit Rev Oncog 3:257-282.
Vojtesek B., Bartek J., Midgley C.A., Lane D.P. (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244.
Cattoretti G., Pileri S., Parravicini C. (1993) Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171:83-98.
Bodner S.M., Minna J.D., Jensen S.M. (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749.
Kastan M.B., Radin A.I., Kuerbitz S.J. (1991) Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51:4279-4286.
Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
Hall P.A., McKee P.H., Menage H.D., Dover R., Lane D.P. (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203-207.
Stewart A., Parmar K. (1993) Meta-analysis of the literature or of individual patient data: Is there a difference?. Lancet 341:418-422.
Cappelleri J., Loannidis J., Schmid C. (1996) Large trials versus meta-analysis of smaller trials. JAMA 276:1332-1338.
